Table 4. Bivariable and multivariable Cox regression analysis for predictors of mortality among breast t cancer patients in UOGCSRH from February 2015 to February 2020.

Characteristics	Survival status		Bivariable	Multivariable
	Death	Censor	cHR (95% CI	aHR (95% CI)
Place of residence
Urban	38(9.27%)	138(33.66%)	1	1
Rural	101(24.63%)	133(32.45%)	1.74(1.26,2.4)*	1.25(0.88,1.78)
Menopause
Premenopausal	45(10.98%)	169(41.22%)	1
Postmenopausal	94(22.93%)	102(24.88%)	2.46 (1.65,3.98)*	2.03(1.37,3)**
Comorbidit
No	25(6.1%)	172(41.95%)	1
Yes	114(27.8%)	99(24.15%)	2.304 (1.61,3.3)*	1.5(1.01,2.21)**
Stage of breast cancer
I	5(1.22%)	10(2.43%)	1	1
II	5 (1.22%)	93(22.68%)	2.93(0.02,5.64)	2.54(0.62,6.02)
III	29 (7.07%)	127(30.98%)	9.88 (6.37,12.79)*	9.43(6.3,11.03)**
IV	108(26.34%)	35(18.54%)	11.01(4.73,11.17)*	10.44(8.03,11.03)**
Histology grade
Grade I	9(20.1%)	34(79.1%)	1	1
Grade II	29(25%)	87(75%)	1.86(0.4,2.22)	1.32(0.77,2.22)
Grade III	71(28.28)	150(59.76)	2.88(1.25,11.23)*	2.12(1.26, 3.55)**
No of involved lymph node
< = 3	30 (7.32%)	210 (51.2%)	1	1
4–9 nodes	62 (15.12%)	35 (18.54%)	5.27(3.87,9.68)*	4.78(2.19, 10.43)**
> = 10	47 (11.46%)	26 (6.34%)	13.6(7.27, 20.8)*	12.58(5.19,30.46)**
Lymph node status
Negative	115(28.05%)	60 (14.63%)	1	1
Positive	38 (9.27%)	197(48.05%)	1.92(1.13,2.41)*	1.68(0.56,5.05)
Hormone therapy
Yes	30(15.54)	163(84.4%)	1	1
No	109(50.23) %)	108(49.76%)	2.87(2.05, 4.02)*	2.19(1.52, 3.16)**

CI; confidence interval, aHR; adjusted Hazard ratio, cHR: crude hazard ratio

* indicates that the variables significantly associated with the outcome at bivariable analysis 95% level of significant (< 0.05)

** indicates that the variables significantly associated with the outcome at multivariable analysis 95% level of significant (< 0.05).